UNSPSC 51432609: Zankiren hydrochloride

This classification denotes the hydrochloride form of an antihypertensive agent with the molecular formula C35H55N5O6S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier I36B16A34Q, chemically known as 4-thiazolepropanamide, n-((1s,2r,3s)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl)-alpha-(((2s)-2-(((4-methyl-1-piperazinyl)sulfonyl)methyl)-1-oxo-3-phenylpropyl)amino)-, (alphas)- but more generally known as zankiren, which bears US NIH Compound Identifier 3036088.

UNSPSC 51432609 Zankiren hydrochloride is a Commodity code covering pharmaceutical active ingredients and finished medications procured by state and local health agencies, fire departments, and health benefit programs. The scope encompasses emergency medical supplies, pharmacy benefit program products, and wholesale pharmaceutical distribution under state and local cooperative purchasing frameworks. Issuing bodies span municipal fire rescue departments, state health and human services commissions, and multistate cooperative purchasing alliances administering contracts for participating state and local facilities. The City of Tampa Fire Rescue, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the institutional breadth: municipal emergency services, state-level health policy and benefit administration, and interstate cooperative purchasing vehicles that aggregate demand across multiple jurisdictions and facility types.

Recent activity concentrates in Florida, Texas, and Minnesota, with multistate cooperative vehicles expanding reach to additional states including Oregon. The City of Tampa issued IFB 26P00188 in April 2026 for advanced life support medications (labetalol, epinephrine, adenosine, diltiazem) for Tampa Fire Rescue, with sealed bids due April 8, 2026, estimated contract value $40,000, and a one-year term with two optional one-year renewals and unilateral extension rights for up to three 30-day periods; the solicitation carries a 5 percent SLBE bid discount capped at $10,000. The Texas HHS Commission issued RFI HHS0017013 in March 2026 seeking vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager and wholesaler channels, with response due April 3, 2026. The Minnesota Department of Administration's MMCAP issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products through AmerisourceBergen (Cencora), Cardinal Health, and Morris & Dickson, with proposals due March 26, 2026 and contract effectiveness July 1, 2026; evaluation weighted price competitiveness at 75 percent and required vendors to maintain relationships with at least two of three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act standards.